Every Form 4 that Jazz Pharmaceuticals, Inc. (JAZZ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow JAZZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JAZZ filings page.
Jazz Pharmaceuticals plc (JAZZ) reported that Executive Vice President and Chief Legal Officer Neena M. Patil sold 1,200 ordinary shares on September 10, 2026 at an average price of $240.94 per share in an open-market or private transaction. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on February 26, 2026 and is described as non-discretionary. Following this transaction, Patil directly holds 47,671 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc (JAZZ) reported insider activity by President & CEO Renee D. Gala on September 8, 2026. Gala had 1,967 ordinary shares withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units, and separately sold 2,000 ordinary shares at $243.03 per share in a sale described as an open market or private transaction made automatically under a Rule 10b5-1 trading plan adopted on June 4, 2026.
Jazz Pharmaceuticals plc (JAZZ) reported that officer Mary Elizabeth Henderson, Senior Vice President of Technical Operations, disposed of ordinary shares on September 8, 2026 to cover tax obligations from vesting restricted stock units. A total of 1,427 shares were delivered or withheld for payment of tax liability, and no Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc (JAZZ) reported that officer Mary Elizabeth Henderson, SVP, Technical Operations, had shares withheld on August 31, 2026 to cover taxes from the vesting of previously granted restricted stock units. Two transactions disposed of a total of 2,092 Ordinary Shares at per‑share prices around the mid‑$240s.
Jazz Pharmaceuticals plc (JAZZ) reported that director Mark Douglas Smith had shares withheld on August 31, 2026 to cover tax obligations from the vesting of previously granted restricted stock units. A total of 1,706 Ordinary Shares were disposed of through tax-withholding transactions at prices around the mid-$240s per share. No Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc (JAZZ) director Norbert G. Riedel reported dispositions of Ordinary Shares on August 31, 2026 to cover tax obligations from the vesting of previously granted restricted stock units. A total of 1,706 shares were delivered or withheld for taxes, and an entity-related trust holds 10,630 Ordinary Shares indirectly after the reported transactions. No Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc director Ted W. Love reported dispositions of 743 Ordinary Shares on August 31, 2026. Two separate share withholdings of 6 and 737 shares were used to pay tax obligations triggered by the vesting of previously granted restricted stock units. These were administrative tax-withholding events, not open-market sales, and no Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc (JAZZ) reported insider activity by director Laura Hamill involving dispositions of ordinary shares on August 31, 2026. Two transactions totaling 1,706 shares were delivered or withheld to pay tax obligations arising from the vesting of previously granted restricted stock units, rather than open-market sales. No Rule 10b5-1 trading plan is reported for these transactions.
Jazz Pharmaceuticals plc (JAZZ) reported that director Jennifer E. Cook disposed of ordinary shares on August 31, 2026 to satisfy tax obligations from the vesting of previously granted restricted stock units. A total of 1,706 ordinary shares were delivered or withheld for tax, in two transactions priced at $244.0643 and $241.39 per share, respectively. No Rule 10b5-1 trading plan is reported in connection with these transactions.
Jazz Pharmaceuticals plc (JAZZ) director Patrick G. Enright reported two dispositions of ordinary shares on August 31, 2026, when 14 shares at $244.64 and 1,692 shares at $241.39 were delivered or withheld to pay tax obligations arising from the vesting of previously granted restricted stock units; these were not open-market sales and no Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc (JAZZ) director Heather Ann McSharry reported two dispositions of Ordinary Shares on August 31, 2026 to cover tax obligations from the vesting of previously granted restricted stock units. A total of 1,855 shares were delivered or withheld for tax payment, and no Rule 10b5-1 plan is reported.
Jazz Pharmaceuticals plc (JAZZ) reported that director Patrick Kennedy disposed of shares in connection with equity compensation on August 31, 2026. Two transactions used a total of 1,855 Ordinary Shares to pay tax obligations arising from the vesting of previously granted restricted stock units, with no open-market purchases or sales reported and no Rule 10b5-1 trading plan indicated.
Jazz Pharmaceuticals plc (JAZZ) reported that director Rick E. Winningham had a total of 1,706 Ordinary Shares delivered or withheld on August 31, 2026 to satisfy tax obligations arising from the vesting of previously granted restricted stock units. These dispositions were not open-market sales and no Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported selling 6,000 Ordinary Shares of JAZZ on September 1, 2026 at $250.13 per share in an open-market or private transaction. On August 31, 2026, he also disposed of 1,219 shares to pay tax liabilities from vesting restricted stock units, including a previously unreported 3,193-share tax withholding from November 3, 2025. The September 1, 2026 sale was executed under a Rule 10b5-1 trading plan adopted on November 26, 2025.
Jazz Pharmaceuticals plc (JAZZ) reported that executive officer Robert Iannone, EVP, Global Head of R&D & CMO, exercised stock options and sold shares on August 27, 2026. He exercised derivative securities covering 57,500 Ordinary Shares at exercise prices of $113.10 and $137.12 per share, acquiring the same number of Ordinary Shares. On the same date, he sold an aggregate of 76,921 Ordinary Shares in multiple transactions at weighted average prices ranging from approximately $247.86 to $252.76 per share. The filing states these trades occurred automatically under a Rule 10b5-1 trading plan adopted on May 28, 2026.
Jazz Pharmaceuticals executive Samantha Pearce, EVP and Chief Commercial Officer, reported that 780 Ordinary Shares were withheld on 2026-08-05 at $261.62 per share to satisfy tax obligations from vesting of previously granted restricted stock units. After this tax-withholding disposition, she directly holds 47,131 Ordinary Shares.
Winningham Rick E reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Rick E Winningham reported an equity award of 1,605 restricted stock units, each representing one ordinary share, granted at $0.0000 per share under the 2007 Non-Employee Directors Stock Award Plan. Subject to continuous service and conditions, the units vest in full on July 23, 2027, bringing his direct holdings to 11,172 ordinary shares.
LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc reported that director Ted W. Love received a grant of 1,605 restricted stock units, each representing a contingent right to receive one ordinary share at a cash price of $0.00 per share.
The award was granted under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to his continuous service and other conditions. Following this grant, Love directly holds 3,132 ordinary shares.
Hamill Laura reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc reported that director Laura Hamill received a grant of 1,605 restricted stock units, each representing one ordinary share, for no cash consideration. These units vest in full on July 23, 2027, subject to continuous service, bringing her direct holdings to 8,538 ordinary shares.
Kennedy Patrick reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Patrick Kennedy reported a grant of 1,605 restricted stock units, each representing one ordinary share, under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to continuous service and conditions, the units vest in full on July 23, 2027, bringing his direct holdings to 8,307 ordinary shares.
Smith Mark Douglas reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Mark Douglas Smith reported an equity compensation grant of 1,605 restricted stock units, each representing a right to receive one ordinary share. The award was made at $0.0000 per share under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to continuous service and other conditions. Following this grant, Smith directly holds 11,285 ordinary shares.
Cook Jennifer E. reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc director Jennifer E. Cook received a grant of 1,605 restricted stock units, each representing one ordinary share, at a reported price of $0.0000 per share. Granted under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan, the units vest in full on July 23, 2027, subject to continuous service and conditions. Following this award, she directly holds 12,442 ordinary shares.
Mulligan Seamus reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Seamus Mulligan received an equity award covering 1,605 ordinary shares through restricted stock units under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. The units vest in full on July 23, 2027, subject to continuous service and conditions. After this award he holds 1,184,633 ordinary shares directly, plus 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family.
McSharry Heather Ann reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Heather Ann McSharry received a grant of 1,605 restricted stock units representing contingent rights to ordinary shares. The award was issued under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to continuous service and certain conditions. Following this grant, McSharry is reported to hold 20,054 ordinary shares directly.
ENRIGHT PATRICK G reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Patrick G. Enright received a grant of 1,605 restricted stock units, each representing a contingent right to one ordinary share upon vesting, under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to continuous service and conditions, the units vest in full on July 23, 2027, bringing his reported holdings for this security to 22,984 shares.
RIEDEL NORBERT G reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc director Norbert G. Riedel received a grant of 1,605 restricted stock units on August 5, 2026 under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each unit represents a contingent right to one ordinary share and will vest in full on July 23, 2027, subject to continuous service and other conditions. Following the award, 8,629 ordinary shares were reported as beneficially owned by the NORBERT G. RIEDEL 2023 TRUST, and a separate indirect holding entry shows 10,630 ordinary shares held by trust.
COZADD BRUCE C reported acquisition or exercise transactions in this Form 4 filing.
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc, reported an equity compensation grant of 1,605 restricted stock units, each representing one ordinary share. The award carries a reported price per share of $0.00 and will vest in full on July 23, 2027, subject to continuous service and other conditions. Following this grant, Cozadd directly holds 362,287 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals director Bruce C. Cozadd sold 6,000 Ordinary Shares on August 3, 2026 at $252.98 per share in a sale described as an open market or private transaction. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on November 26, 2025, and does not represent a discretionary trade. Following this transaction, he directly holds 360,682 shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of JAZZ on July 1, 2026 at an average price of $240.47 per share. The filing shows that Cozadd continues to directly hold 366,682 Ordinary Shares after this transaction.
According to the disclosure, the trade was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the timing was set in advance and was not a discretionary decision by the reporting person.
Jazz Pharmaceuticals EVP and Chief Commercial Officer Samantha Pearce reported a tax-related share disposition. On the vesting of previously granted restricted stock units, 2,527 ordinary shares were withheld at a price of $237.72 per share to cover tax obligations, a non-market transaction classified as a tax-withholding disposition.
After this event, Pearce directly held 47,911 ordinary shares. A footnote also notes that she acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026, reflecting routine employee share purchase activity separate from the tax withholding.
Jazz Pharmaceuticals plc reported a routine insider transaction by its President & CEO, Renee D. Gala. On June 30, 2026, 4,835 ordinary shares were withheld at $237.72 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. This was a tax-withholding disposition, not an open-market sale. Following the transaction, Gala directly holds 147,361 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals EVP and CMO Robert Iannone reported a routine tax-related share disposition. On vesting of previously granted restricted stock units, 3,764 Ordinary Shares were withheld to satisfy tax obligations at $237.72 per share. After this withholding, he directly holds 85,107 Ordinary Shares.
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil had 2,678 Ordinary Shares withheld on June 30, 2026 to cover taxes from vesting restricted stock units. The shares were not sold on the open market but used to satisfy tax obligations.
After this tax-withholding disposition, Patil directly holds 48,871 Ordinary Shares. This type of transaction is routine for equity-based compensation and does not represent a discretionary purchase or sale decision.
Jazz Pharmaceuticals EVP & Chief Financial Officer Philip L. Johnson reported a routine tax-withholding transaction related to equity compensation. On the vesting of previously granted restricted stock units, 3,343 ordinary shares were withheld at $237.72 per share to satisfy tax obligations. After this disposition, he directly holds 56,431 ordinary shares. A footnote also notes he acquired 166 ordinary shares under a Section 423 employee stock purchase plan on May 29, 2026.
Jazz Pharmaceuticals plc director Mark Douglas Smith reported an open-market sale of 1,157 ordinary shares at $230.55 per share. After this transaction, he directly holds 9,680 ordinary shares. According to a disclosed Rule 10b5-1 trading plan adopted on March 9, 2026, the sale occurred automatically and was not a discretionary trade.
Jazz Pharmaceuticals EVP & Chief Legal Officer Neena M. Patil reported an open-market sale of 1,200 ordinary shares on June 10, 2026 at $231.83 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan and occurred automatically. After this transaction, she directly holds 51,549 ordinary shares. A footnote also notes she acquired 123 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala reported a charitable share transfer. On June 3, 2026, she made a bona fide gift of 600 ordinary shares at a stated price of $0.00 per share, reducing her direct holdings to 152,196 shares. A footnote also notes that she acquired 166 ordinary shares through a Section 423 Employee Stock Purchase Plan on May 29, 2026, highlighting ongoing participation in employee equity programs.
Jazz Pharmaceuticals plc director Bruce C. Cozadd sold 6,000 Ordinary Shares of JAZZ in an open-market transaction. The shares were sold at an average price of $235.12 per share. After this sale, he directly holds 372,682 Ordinary Shares of Jazz Pharmaceuticals.
The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the transaction timing was scheduled in advance and was not a discretionary trade by the reporting person.
Jazz Pharmaceuticals plc executive Neena M. Patil, EVP & Chief Legal Officer, reported an open-market sale of 1,192 Ordinary Shares at $236.97 per share. After this transaction, she directly holds 52,626 shares.
The sale was executed automatically under a Rule 10b5-1 trading plan adopted on February 26, 2026, indicating it was pre-scheduled rather than a discretionary trade based on short-term market conditions.
Jazz Pharmaceuticals executive Samantha Pearce reported an exercise-and-sale transaction in company stock. On May 28, 2026, the EVP, Chief Commercial Officer exercised non-qualified stock options to acquire 6,907 ordinary shares at an exercise price of $109.45 per share and sold 6,907 ordinary shares in an open-market transaction at $235.41 per share. Following these transactions, she directly owns 50,272 ordinary shares. The exercised options were granted under the company’s 2011 Equity Incentive Plan and had fully vested by March 2, 2024, and this specific option grant is now fully exercised.
Jazz Pharmaceuticals plc director Seamus Mulligan exercised a non-qualified stock option to acquire 3,415 Ordinary Shares at $138.08 per share. After this exercise, he holds 1,183,028 Ordinary Shares directly and 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family.
The option was originally granted on August 11, 2016 and had fully vested by August 1, 2017. Following this transaction, no shares remain under the exercised option, and there is no remaining derivative position reported in this filing.
Jazz Pharmaceuticals director Rick E. Winningham exercised stock options and sold shares in the company. On May 22, 2026, he sold 2,741 Ordinary Shares in an open-market transaction at $241.57 per share, and exercised 3,415 Non-Qualified Stock Options at a $138.08 exercise price.
The options were originally granted in August 2016 and had fully vested by August 1, 2017. Following these transactions, Winningham directly holds 9,567 Ordinary Shares of Jazz Pharmaceuticals, indicating he retained a meaningful equity stake after the exercise-and-sale activity.
Jazz Pharmaceuticals plc director Heather Ann McSharry reported an open-market sale of 2,000 Ordinary Shares of the company on May 22, 2026 at a price of $241.00 per share. After this transaction, she directly holds 18,449 Ordinary Shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of Jazz Pharmaceuticals on May 1, 2026, at $203.33 per share. After this transaction, he directly holds 378,682 Ordinary Shares.
According to the filing, this sale was executed automatically under a pre-arranged trading plan adopted on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, meaning the timing did not involve a discretionary decision by Cozadd.
Jazz Pharmaceuticals plc director Bruce C. Cozadd sold 6,000 ordinary shares of the company in open-market transactions. The sales occurred on 2026-04-01 at weighted average prices of $190.2220, $190.9383 and $191.7447 per share. According to a footnote, these trades were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the timing was not discretionary. After the transactions, Cozadd directly owned 384,682 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals director Bruce C. Cozadd reported a tax-related share disposition. On the vesting of previously granted restricted stock units, 15,114 Ordinary Shares were withheld at $188.69 per share to satisfy tax obligations, reducing his directly held stake to 390,682 Ordinary Shares. This Form 4 reflects a tax-withholding transaction rather than an open-market trade.
Jazz Pharmaceuticals plc Executive Vice President and Chief Financial Officer Philip L. Johnson reported a tax-related share disposition. On March 5, 2026, 2,615 ordinary shares were withheld at $188.69 per share to cover tax obligations from the vesting of previously granted restricted stock units. After this withholding, he directly held 59,608 ordinary shares.
Jazz Pharmaceuticals plc SVP, Technical Operations Mary Elizabeth Henderson reported a tax-related share disposition. On March 5, 2026, she disposed of 1,394 ordinary shares to satisfy tax obligations from vesting restricted stock units, at a weighted average price of $186.747 per share.
The shares were sold in multiple transactions at prices ranging from $186.1633 to $186.7558. After these transactions, Henderson directly owned 27,334 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc executive reports tax-related share disposition. EVP and Chief Commercial Officer Samantha Pearce had 2,503 Ordinary Shares withheld at $188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. After this tax-withholding transaction, she directly owns 50,272 Ordinary Shares.
Jazz Pharmaceuticals EVP Robert Iannone, Global Head of R&D and CMO, reported a tax-related share disposition. On March 5, 2026, 6,209 ordinary shares were withheld at a price of 188.69 per share to satisfy tax obligations from the vesting of previously granted restricted stock units.
Following this tax-withholding disposition, Iannone directly holds 88,871 ordinary shares of Jazz Pharmaceuticals. This transaction reflects administrative share withholding rather than an open-market purchase or sale.